Volume 12, Issue 6, Pages 539-545 (June 2013) Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials Dr William N Whiteley, PhD, Harold P Adams, MD, Philip MW Bath, FRCP, Eivind Berge, MD, Per Morten Sandset, MD, Martin Dennis, MD, Gordon D Murray, PhD, Ka-Sing Lawrence Wong, MD, Peter AG Sandercock, MD The Lancet Neurology Volume 12, Issue 6, Pages 539-545 (June 2013) DOI: 10.1016/S1474-4422(13)70079-6 Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 1 Association of baseline variables with thrombotic events—myocardial infarction, recurrent ischaemic stroke, deep vein thrombosis, and pulmonary embolism Each square represents the point estimate from a random effects meta-analysis across trials, and the horizontal line the 95% CI. N=number of patients. n=number of events in each meta-analysis. NIHSS=National Institutes of Health stroke scale. The Lancet Neurology 2013 12, 539-545DOI: (10.1016/S1474-4422(13)70079-6) Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 2 Association of baseline variables with haemorrhagic events (intracranial or extracranial haemorrhage) Each square represents the point estimate from a random effects meta-analysis across trials, and the horizontal line the 95% CI. N=number of patients, n=number of events in each meta-analysis. The Lancet Neurology 2013 12, 539-545DOI: (10.1016/S1474-4422(13)70079-6) Copyright © 2013 Elsevier Ltd Terms and Conditions